SCHEMBL6969193

SCHEMBL6969193

CCOC(=O)CCC1CCc2[nH]cnc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 6/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
ALDH1A1 P00352 2/20 0.37
USP2 O75604 1/20 0.36
ALOX15 P16050 1/20 0.36
KLK7 P49862 2/20 0.35
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
PDK1 Q15118 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
RAB9A P51151 1/20 0.33
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
ADRA1A P35348 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6969189 0.99 TDP1 (0.38) TDP1L3MBTL1ALDH1A1USP2ALOX15
SCHEMBL6967541 0.88 JAK2 (0.39) TDP1ALDH1A1KDM4EHSD17B10TP53
Hydrochloric Acid SCHEMBL6961742 0.81 ADRA1A (0.37) HSD17B10ADRA1A
SCHEMBL8482514 0.80 PDK1 (0.46) ALDH1A1ALOX15KDM4EHSD17B10TSHR
SCHEMBL6967215 0.75 KMT2A (0.43) TDP1L3MBTL1ALDH1A1KDM4EHSD17B10
SCHEMBL6849697 0.73 ALDH1A1 (0.44) TDP1ALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL6849837 0.73 ADRA1A (0.38) ADRA1A
SCHEMBL26828383 0.73 ALDH1A1 (0.41) TDP1L3MBTL1ALDH1A1USP2ALOX15
Hydrochloric Acid SCHEMBL6846931 0.72 ALDH1A1 (0.43) TDP1ALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL6849832 0.72 ADRA1A (0.35) TDP1ALDH1A1ADRA1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610721-B2 Imidazo heterocyclic compounds NOVO NORDISK A/S (DK) 2003-08-26 US disclosed
EP-1268483-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-20010049385-A1 Imidazo heterocyclic compounds HIGH POINT PHARMACEUTICALS, LLC 2001-12-06 US disclosed
WO-2001068651-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049385-A1 Imidazo heterocyclic compounds HRH4, HRH3, HRH2 TDP1 4444/4885L3MBTL1 3389/4885ALDH1A1 1310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.